NervGen Pharma (NGEN) news

CMA CGM - From 2029, this facility, developed by Engie, will supply 7,000 tonnes of biomethane (equivalent to 100 GWh) each year to the CMA CGM fleet

CMA CGM has announced a new initiative in its ongoing efforts to achieve carbon neutrality by 2050, with a facility developed by Engie set to supply 7,000 tonnes of biomethane annually, equivalent to 100 gigawatt-hours (GWh), to the CMA CGM fleet starting in 2029. This development aligns with the…

Nervgen Pharma Corp - Enrollment completion for restore expected H2 2027; topline data in H1 2028

NervGen Pharma Corp has announced that enrollment for the RESTORE Phase 3 clinical trial of its lead candidate, NVG-291, is expected to be completed by the second half of 2027. The company anticipates that topline data from the study will be available in the first half of 2028. The RESTORE trial is…

Nevgold announces the passing of board member Tim Dyhr

Nevgold Corp. (TSX: NVL) announced on September 23, 2026, the passing of Tim Dyhr, a long-standing member of its board of directors. Dyhr, who had served on the board since 2018, was known for his extensive experience in the mining sector and his contributions to the company’s strategic direction.…

Nervgen Pharma Corp: Leerink Partners initiates coverage with outperform rating; price target $10

Leerink Partners has initiated coverage of NervGen Pharma Corp. (NASDAQ: NGEN) with an "Outperform" rating and a price target of $10 per share , according to a recent report. The decision follows the company’s recent progress in advancing its lead therapeutic candidate, NVG-291, through clinical…

Nervgen Pharma files $250M mixed securities shelf